SPH(ZX)003

SPH(ZX)003 is an investigational small molecule inhibitor of tyrosine kinase 2 (TYK2) being developed by Shanghai Shangyao Chinese-Western Pharmaceutical, a subsidiary of Shanghai Pharmaceuticals. TYK2 is a member of the Janus kinase (JAK) family that mediates signaling for cytokines such as interleukin-23 (IL-23), IL-12, and Type I interferons, which are critical in the pathogenesis of various autoimmune and inflammatory diseases. By selectively inhibiting TYK2, SPH(ZX)003 aims to provide therapeutic benefits for conditions like psoriasis and inflammatory bowel disease while potentially avoiding the side effects associated with non-selective JAK inhibitors. The asset is currently in the IND-enabling stage of development, preparing for clinical trials in autoimmune indications.